Acura Pharmaceuticals
ACUR
ACUR was delisted on the 22nd of February, 2017.
27 hedge funds and large institutions have $9.01M invested in Acura Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 9 closing their positions.
72% more capital invested
Capital invested by funds: $5.25M → $9.01M (+$3.76M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less funds holding
Funds holding: 33 → 27 (-6)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$25.3K |
| 2 |
Renaissance Technologies
New York
|
+$23.9K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$1.28K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$383 |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$207 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RIL
Rothschild Investment LLC
Chicago,
Illinois
|
-$45K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
-$30K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$20K |
| 4 |
Goldman Sachs
New York
|
-$19K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8K |
ACUR Hedge Fund Activity: Q1 2015 in Review
27 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Acura Pharmaceuticals (ACUR) for Q1 2015, worth a combined $9.01M — up 72% from $5.25M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ACUR and 3 opened new positions — a net loss of 6 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $25.3K. The largest seller was Rothschild Investment LLC, exiting entirely with an estimated $45K sold.
- 27 institutional investors held Acura Pharmaceuticals (ACUR) as of Q1 2015, down from 33 in Q4 2014.
- Funds reported $9.01M of Acura Pharmaceuticals stock for Q1 2015, up 72% quarter-over-quarter.
- 3 funds opened new Acura Pharmaceuticals positions in Q1 2015 and 9 closed out, a net change of -6 holders.
- The largest Acura Pharmaceuticals buyer in Q1 2015 was Jacobs Levy Equity Management, an estimated $25.3K added.
- The largest Acura Pharmaceuticals seller in Q1 2015 was Rothschild Investment LLC, an estimated $45K sold.
Based on aggregated 13F filings for Q1 2015.